TipRanks
Ionis Pharmaceuticals (MX:IONS)
:IONS
Mexico Market
IONS
Ionis Pharmaceuticals
RESEARCH TOOLSreports

Ionis Pharmaceuticals (IONS) Stock News & Sentiment

1 Followers
Ionis Stock Sinks 10% as Analysts Cut Targets After Pelacarsen Trial Miss
Premium
Market News
Ionis Stock Sinks 10% as Analysts Cut Targets After Pelacarsen Trial Miss
12d ago
AZN
NVS
Novartis Stock (NVS) Sinks on Another Setback, Muscle-Wasting Disorder Drug Disappoints
Premium
Market News
Novartis Stock (NVS) Sinks on Another Setback, Muscle-Wasting Disorder Drug Disappoints
12d ago
NVS
IONS
Ionis Buy Rating Reiterated as Analyst Sees Limited Impact from Lp(a)HORIZON Setback and Maintains $100 Price Target
Premium
Ratings
Ionis Buy Rating Reiterated as Analyst Sees Limited Impact from Lp(a)HORIZON Setback and Maintains $100 Price Target
13d ago
IONS
Ionis Pharmaceuticals Updates on Novartis Pelacarsen Trial Outcome
Premium
Company Announcements
Ionis Pharmaceuticals Updates on Novartis Pelacarsen Trial Outcome
15d ago
8K
IONS
Ionis Pharmaceuticals: Buy Rating Backed by FDA Approval of Zanvastro and Strengthened Neurology Pipeline Upside
Premium
Ratings
Ionis Pharmaceuticals: Buy Rating Backed by FDA Approval of Zanvastro and Strengthened Neurology Pipeline Upside
15d ago
IONS
Ionis Pharmaceuticals: Buy Rating Reiterated as Early Zanvastro Approval, Rare-Disease Portfolio Strength, and Valuation Support Back Unchanged $115 Price Target
Premium
Ratings
Ionis Pharmaceuticals: Buy Rating Reiterated as Early Zanvastro Approval, Rare-Disease Portfolio Strength, and Valuation Support Back Unchanged $115 Price Target
16d ago
IONS
Ionis wins FDA approval for ZANVASTRO in Alexander disease
Premium
Company Announcements
Ionis wins FDA approval for ZANVASTRO in Alexander disease
16d ago
8K
IONS
More MX:IONS News >

IONS News on the Web

Ionis Has Its First Neurology Launch, But Can Zanvastro Justify Its $285,000 Price?
Insider Monkey
Neutral
BofA Sees Limited Damage from Novartis (NVS)’ Pelacarsen Miss While Citi Looks Towards Ionis (IONS)
Insider Monkey
Bullish
Ionis Pharmaceuticals, Inc. at Wells Fargo Healthcare Conference Transcript
GuruFocus News
Neutral
Bank of America Securities Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)
TipRanks News
Neutral
Ionis Pharmaceuticals price target lowered to $56 from $69 at Goldman Sachs
TipRanks News
Neutral
Ionis Pharmaceuticals price target lowered to $85 from $95 at Canaccord
TipRanks News
Neutral
Ionis Pharmaceuticals price target lowered to $54 from $61 at BMO Capital
TipRanks News
Bearish
Ionis Stock Slides As Key Heart Drug Trial Fails
TipRanks News
Bearish

News Score - Last 7 Days

Neutral
MX:IONS
Sector Average
Media Buzz
This Week10 articles
Weekly Average18 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is MX:IONS’s Media Buzz Sentiment?
10 articles about MX:IONS were published this week. In an average week, 18 articles are published.
    What is MX:IONS’s weekly average amount of articles?
    In an average week, 18 articles about MX:IONS are published.
      What is MX:IONS’s News Sentiment?
      100% of articles about MX:IONS were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        CRLCharles River Labs
        DFTXDefinium Therapeutics
        AMRXAmneal Pharmaceuticals
        SMMTSummit Therapeutics
        ABEOAbeona Therapeutics
        Showing the stocks with the most bullish news sentiment over the past week